caa a22 4500 463256166 CHVBK 20180405153356.0 cr unu---uuuuu 170326e20071001xx s 000 0 eng 10.1007/s00277-007-0326-2 doi (NATIONALLICENCE)springer-10.1007/s00277-007-0326-2 Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission [Elektronische Daten] [Angelo Carella, Enrica Lerma] In the present report, we address the question if the reduction of standard dosage of imatinib mesylate (IM) in imatinib-intolerant chronic myeloid leukemia (CML) patients with undetectable residual disease may impair their outcome. Four patients are described. The median follow up from the beginning of IM therapy was 35months (33-59). The median duration of real-time quantitative polymerase chain reaction (RQ-PCR) negativity on IM 200mg daily was 17months (4-37). We hypothesize that in IM intolerant CML patients with complete molecular remission, the compound dosage might be safely reduced to a lower than standard dose without to lose the response. A tight molecular monitoring of such patients should be required. Springer-Verlag, 2007 CML nationallicence BCR-ABL nationallicence Molecular remission nationallicence Imatinib mesylate nationallicence Drug resistance nationallicence Drug intolerance nationallicence Tyrosine kinase inhibitors nationallicence Carella Angelo Divisione Ematologia 1, Azienda Ospedaliera Universitaria San Martino, Monoblocco XI piano Ponente, L.go R. Benzi, 10, 16132, Genova, Italy aut Lerma Enrica Hematology 1 and Stem Cell Transplant Unit, Azienda Ospedaliera Universitaria San Martino, Genova, Italy aut Annals of Hematology Springer-Verlag 86/10(2007-10-01), 749-752 0939-5555 86:10<749 2007 86 277 https://doi.org/10.1007/s00277-007-0326-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00277-007-0326-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Carella Angelo Divisione Ematologia 1, Azienda Ospedaliera Universitaria San Martino, Monoblocco XI piano Ponente, L.go R. Benzi, 10, 16132, Genova, Italy aut NATIONALLICENCE 700 1- Lerma Enrica Hematology 1 and Stem Cell Transplant Unit, Azienda Ospedaliera Universitaria San Martino, Genova, Italy aut NATIONALLICENCE 773 0- Annals of Hematology Springer-Verlag 86/10(2007-10-01), 749-752 0939-5555 86:10<749 2007 86 277 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer